Neurocrine Biosciences
NBIX
#1365
Rank
S$20.84 B
Marketcap
S$207.31
Share price
-2.48%
Change (1 day)
28.22%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): S$8.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$8.63. In 2025 the company made an earnings per share (EPS) of S$6.20 an increase over its 2024 EPS that were of S$4.35.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$8.6138.93%
2025S$6.2042.6%
2024S$4.3533.07%
2023S$3.2757.76%
2022S$2.0769.47%
2021S$1.22-78.21%
2020S$5.61990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.100.62%
2016S-$2.0857.28%
2015S-$1.3325.61%
2014S-$1.0518.84%
2013S-$0.89-1085.71%
2012S$0.09005

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$1.69-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$2.65-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$36.31 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$1.18-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.61-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$4.50-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$38.47-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.45-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK